Last reviewed · How we verify
NCT04383756
Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation
EARLY_PHASE1 trial testing Donor Blood in Transfusion Related Complication. Withdrawn.
1 July 2021
Quick facts
| Lead sponsor | Vanderbilt University Medical Center |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 December 2020 |
| Primary completion | 1 July 2021 |
| Estimated completion | 1 July 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Donor Blood — full drug profile →
- Banked Blood — full drug profile →
Conditions studied
- Transfusion Related Complication — all drugs for Transfusion Related Complication →
- Liver Transplant — all drugs for Liver Transplant →
Sponsor
Vanderbilt University Medical Center
Who can join
18 and older, any sex, with Transfusion Related Complication or Liver Transplant. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Use of allogenic banked blood products
Time frame: perioperative up to 72 hours post operative
Measured by the number of allogenic banked blood products used -
Economic cost
Time frame: perioperative up to 72 hours post operative
Total cost of perioperative transfusions
Sponsor's own description
We will study 40 matched patients. 20 patients will receive leukoreduced whole blood from the solid organ donor. These 20 patients will be compared to 20 historical matched controls with regards to allogenic blood product usage and other physiologic markers
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04383756
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transfusion Related Complication
Currently open trials in the same condition.
- NCT06399536 — Individualized ANH for Non-cardiac Surgery · NA · recruiting
- NCT05806346 — Goal-directed vs. Empirical Tranexamic Acid Administrationin Cardiovascular Surgery · NA · recruiting
- NCT06403163 — Transfusion Surveillance in Anaesthesia · recruiting
- NCT03999229 — S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion · Phase 1 · recruiting
Other Vanderbilt University Medical Center trials
Trials by the same sponsor.
- NCT07005037 — Swallowing Impairments in ICU Survivors and Community-Dwelling Adults · not yet recruiting
- NCT07527273 — Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · NA · not yet recruiting
- NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis · Phase 4 · not yet recruiting
- NCT07431541 — Topical Carboxytherapy Paste Following Microneedling · Phase 1, PHASE2 · not yet recruiting
- NCT07224711 — The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04383756 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
- Last refreshed: 21 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04383756.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing